A number of different hypertension treatments are available to physicians with the 2017 American Heart Association guidelines recommending initiation of anti-hypertensive drug therapy with first-line agents that include thiazide diuretics, calcium channel blockers (CCBs), and ACE inhibitors or Angiotensin-receptor blockers (ARBs) (Whelton et al., 2017). But when should you use an angiotensin receptor blocker (ARBs) or an angiotensin-converting enzyme inhibitor (ACEi)? How about a calcium channel blocker? When is there a need for triple therapy in hypertension management? and what can we learn from real-world evidence? These are some of the questions explored by the panel of experts.